These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Surgical treatment of giant pituitary adenomas: strategies and results in a series of 95 consecutive patients. Mortini P; Barzaghi R; Losa M; Boari N; Giovanelli M Neurosurgery; 2007 Jun; 60(6):993-1002; discussion 1003-4. PubMed ID: 17538372 [TBL] [Abstract][Full Text] [Related]
24. Analysis of Ki67, HMGA1, MDM2, and RB expression in nonfunctioning pituitary adenomas. Yao X; Gao H; Li C; Wu L; Bai J; Wang J; Li Y; Zhang Y J Neurooncol; 2017 Apr; 132(2):199-206. PubMed ID: 28255749 [TBL] [Abstract][Full Text] [Related]
25. Significance of proliferating cell nuclear antigen index in predicting pituitary adenoma recurrence. Hsu DW; Hakim F; Biller BM; de la Monte S; Zervas NT; Klibanski A; Hedley-Whyte ET J Neurosurg; 1993 May; 78(5):753-61. PubMed ID: 8096873 [TBL] [Abstract][Full Text] [Related]
26. Flow cytometric DNA ploidy and cells phase fractions in recurrent human pituitary adenomas. A correlative study of flow cytometric analysis and the expression of proliferating cell nuclear antigen. Chae YS; Flotte T; Hsu DW; Preffer F; Hedley-Whyte ET Gen Diagn Pathol; 1996 Oct; 142(2):89-95. PubMed ID: 8950573 [TBL] [Abstract][Full Text] [Related]
27. Predictive markers of pituitary adenoma behavior. Kontogeorgos G Neuroendocrinology; 2006; 83(3-4):179-88. PubMed ID: 17047381 [TBL] [Abstract][Full Text] [Related]
28. Clinical and Pathologic Characteristics Predicted the Postoperative Recurrence and Progression of Pituitary Adenoma: A Retrospective Study with 10 Years Follow-Up. Lv L; Yin S; Zhou P; Hu Y; Chen C; Ma W; Jiang Y; Wang Z; Jiang S World Neurosurg; 2018 Oct; 118():e428-e435. PubMed ID: 29981466 [TBL] [Abstract][Full Text] [Related]
29. Objective criteria for successful transsphenoidal removal of suprasellar nonfunctioning pituitary adenomas. A prospective study. Honegger J; Ernemann U; Psaras T; Will B Acta Neurochir (Wien); 2007 Jan; 149(1):21-9; discussion 29. PubMed ID: 17086476 [TBL] [Abstract][Full Text] [Related]
30. Tumor shrinkage assessed by volumetric MRI in long-term follow-up after fractionated stereotactic radiotherapy of nonfunctioning pituitary adenoma. Kopp C; Theodorou M; Poullos N; Jacob V; Astner ST; Molls M; Grosu AL Int J Radiat Oncol Biol Phys; 2012 Mar; 82(3):1262-7. PubMed ID: 21530099 [TBL] [Abstract][Full Text] [Related]
31. Integration of surgery with fractionated stereotactic radiotherapy for treatment of nonfunctioning pituitary macroadenomas. Paek SH; Downes MB; Bednarz G; Keane WM; Werner-Wasik M; Curran WJ; Andrews DW Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):795-808. PubMed ID: 15708259 [TBL] [Abstract][Full Text] [Related]
32. Low aryl hydrocarbon receptor-interacting protein expression is a better marker of invasiveness in somatotropinomas than Ki-67 and p53. Kasuki Jomori de Pinho L; Vieira Neto L; Armondi Wildemberg LE; Gasparetto EL; Marcondes J; de Almeida Nunes B; Takiya CM; Gadelha MR Neuroendocrinology; 2011; 94(1):39-48. PubMed ID: 21178332 [TBL] [Abstract][Full Text] [Related]
33. Endoscopic transsphenoidal treatment in recurrent and residual pituitary adenomas--first experience. Rudnik A; Zawadzki T; Gałuszka-Ignasiak B; Bazowski P; Duda I; Wojtacha M; Rudnik AI; Krawczyk I Minim Invasive Neurosurg; 2006 Feb; 49(1):10-4. PubMed ID: 16547875 [TBL] [Abstract][Full Text] [Related]
34. Both invasiveness and proliferation criteria predict recurrence of non-functioning pituitary macroadenomas after surgery: a retrospective analysis of a monocentric cohort of 120 patients. Lelotte J; Mourin A; Fomekong E; Michotte A; Raftopoulos C; Maiter D Eur J Endocrinol; 2018 Mar; 178(3):237-246. PubMed ID: 29259039 [TBL] [Abstract][Full Text] [Related]
35. Pituitary adenomas in childhood and adolescence. Kane LA; Leinung MC; Scheithauer BW; Bergstralh EJ; Laws ER; Groover RV; Kovacs K; Horvath E; Zimmerman D J Clin Endocrinol Metab; 1994 Oct; 79(4):1135-40. PubMed ID: 7525627 [TBL] [Abstract][Full Text] [Related]
36. Prognostic factors in prolactin pituitary tumors: clinical, histological, and molecular data from a series of 94 patients with a long postoperative follow-up. Raverot G; Wierinckx A; Dantony E; Auger C; Chapas G; Villeneuve L; Brue T; Figarella-Branger D; Roy P; Jouanneau E; Jan M; Lachuer J; Trouillas J; J Clin Endocrinol Metab; 2010 Apr; 95(4):1708-16. PubMed ID: 20164287 [TBL] [Abstract][Full Text] [Related]
37. Systematic Investigation of Expression of G2/M Transition Genes Reveals CDC25 Alteration in Nonfunctioning Pituitary Adenomas. Butz H; Németh K; Czenke D; Likó I; Czirják S; Zivkovic V; Baghy K; Korbonits M; Kovalszky I; Igaz P; Rácz K; Patócs A Pathol Oncol Res; 2017 Jul; 23(3):633-641. PubMed ID: 28004354 [TBL] [Abstract][Full Text] [Related]
38. Clinicopathological analysis of nonfunctioning pituitary adenomas in patients younger than 25 years of age. Yamaguchi-Okada M; Inoshita N; Nishioka H; Fukuhara N; Yamada S J Neurosurg Pediatr; 2012 May; 9(5):511-6. PubMed ID: 22546029 [TBL] [Abstract][Full Text] [Related]
39. A two‑circRNA signature predicts tumour recurrence in clinical non‑functioning pituitary adenoma. Guo J; Wang Z; Miao Y; Shen Y; Li M; Gong L; Wang H; He Y; Gao H; Liu Q; Li C; Zhang Y Oncol Rep; 2019 Jan; 41(1):113-124. PubMed ID: 30542712 [TBL] [Abstract][Full Text] [Related]